

Applicants: Sawyers et al.
U.S. Serial No.: 10/022,115
Filed: December 14, 2001
Page: 2

- b. subjecting the mouse to the composition or treatment; and,
- c. determining the effect of the composition or treatment on the growth of the xenograft in said mouse.--

~~22~~
~~--2~~ (New) The method of claim 2, wherein the detecting step comprises comparing the growth of the xenograft in the mouse to the growth of the xenograft in at least another immune deficient mouse that did not receive the treatment.--

~~23~~
~~--3~~ (New) The method of claim 2, wherein the providing step provides an immune deficient mouse bearing a subcutaneous xenograft.--

~~24~~
~~--4~~ (New) The method of claim 2, wherein the providing step provides an immune deficient mouse bearing an intraprostatic xenograft.--

~~25~~
~~--5~~ (New) The method of claim 2, wherein the providing step provides an immune deficient mouse bearing a xenograft within a bone marrow cavity of the mouse.--

~~26~~
~~--6~~ (New) The method of claim 2, wherein:

- a. step (b) subjects the xenograft mouse to a composition or treatment the efficacy of which, respectively, is not known for treating human prostate cancer; and,
- b. step (c) determines that the treatment or composition is efficacious in impairing the growth of the human prostate cancer xenograft in the mouse.--

~~27~~
~~--7~~ (New) An efficacious composition assessed according to the method of claim 7.--

Applicants: Sawyers et al.
U.S. Serial No.: 10/022,115
Filed: December 14, 2001
Page: 3

²⁸
~~--29~~ (New) An efficacious treatment assessed according to the method of claim 7.--

²⁹
~~--30~~ (New) A method for impairing the progression of human prostate cancer comprising:
providing the composition of claim 8 to a subject comprising human prostate cancer
cells.--

³⁰
~~--31~~ (New) The method of claim 10, wherein the subject is a human.--

³¹
~~--32~~ (New) The method of claim 10, wherein the subject is a mouse bearing a human prostate
cancer xenograft.--

³²
~~--33~~ (New) A method for impairing the progression of human prostate cancer comprising:

a. providing the treatment of claim 9 to a subject comprising human prostate cancer
cells.--

³³
~~--34~~ (New) The method of claim 13, wherein the subject is a human.--

³⁴
~~--35~~ (New) The method of claim 13, wherein the subject is a mouse bearing a human prostate
cancer xenograft.--

Remarks

Claim 1 was pending. Applicants have cancelled claim 1 herein without prejudice and added
new claims 2-15. Accordingly, claims 2-15 are being examined.